Novel (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: peroxisome proliferator-activated receptor γ selective agonists with protein-tyrosine phosphatase 1B inhibition.
暂无分享,去创建一个
Mamoru Kanda | Kazuya Otake | Satoru Azukizawa | Masaki Fukui | Kazuyoshi Kunishiro | Hikaru Kamemoto | Tomohiro Miike | Masayasu Kasai | Hiroaki Shirahase | Kazuya Otake | Satoru Azukizawa | Masaki Fukui | H. Kamemoto | Tomohiro Miike | K. Kunishiro | M. Kasai | H. Shirahase | M. Kanda
[1] B. Spiegelman,et al. International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors , 2006, Pharmacological Reviews.
[2] D. Crabb,et al. The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease. , 2000, Liver.
[3] Weiqi Wang,et al. Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities. , 2005, Journal of medicinal chemistry.
[4] M. Reitman,et al. WY14,643, a Peroxisome Proliferator-activated Receptor α (PPARα) Agonist, Improves Hepatic and Muscle Steatosis and Reverses Insulin Resistance in Lipoatrophic A-ZIP/F-1 Mice* , 2002, The Journal of Biological Chemistry.
[5] D. Hum,et al. Safety issues and prospects for future generations of PPAR modulators. , 2007, Biochimica et biophysica acta.
[6] C. Tack,et al. Thiazolidinedione derivatives in type 2 diabetes mellitus. , 2006, The Netherlands journal of medicine.
[7] J. Yano,et al. A Novel Selective Peroxisome Proliferator-Activated Receptor α Agonist, 2-Methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), Potently Decreases Plasma Triglyceride and Glucose Levels and Modifies Lipoprotein Profiles in KK-Ay Mice , 2004, Journal of Pharmacology and Experimental Therapeutics.
[8] Lebovitz He,et al. Insulin resistance and its treatment by thiazolidinediones. , 2001 .
[9] R. Saladin,et al. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. , 2000, Biochemical and biophysical research communications.
[10] Kenji Takahashi,et al. 2-Acyl-tetrahydroisoquinoline-3-carboxylic acids: lead compounds with triple actions, peroxisome proliferator-activated receptor α/γ agonist and protein-tyrosine phosphatase 1B inhibitory activities. , 2011, Chemical & pharmaceutical bulletin.
[11] D. Krische. The glitazones: proceed with caution. , 2000, The Western journal of medicine.
[12] B. Henke. Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. , 2004, Journal of medicinal chemistry.
[13] J. Proietto,et al. Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real‐life experience from a tertiary hospital , 2004, Medical Journal of Australia.
[14] M. Essop,et al. Wy-14,643 and fenofibrate inhibit mitochondrial respiration in isolated rat cardiac mitochondria. , 2006, Mitochondrion.
[15] D. Lai,et al. Rodent Carcinogenicity of Peroxisome Proliferators and Issues on Human Relevance , 2004, Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews.
[16] Michael Lehrke,et al. The Many Faces of PPARγ , 2005, Cell.
[17] M. Quon,et al. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. , 2005, Diabetes care.
[18] R. Ulrich,et al. Profiling of hepatic gene expression in rats treated with fibric acid analogs. , 2004, Mutation research.
[19] B. Staels,et al. PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome , 2006 .
[20] B. Staels. Fluid retention mediated by renal PPARγ , 2005 .
[21] N. Blomberg,et al. Structure of the PPARα and -γ Ligand Binding Domain in Complex with AZ 242; Ligand Selectivity and Agonist Activation in the PPAR Family , 2001 .
[22] Kenji Takahashi,et al. Synthesis and Biological Evaluation of (S)-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acids: A Novel Series of PPARγ Agonists , 2008 .
[23] C. Moxham,et al. PTP1B inhibition and antihyperglycemic activity in the ob/ob mouse model of novel 11-arylbenzo[b]naphtho[2,3-d]furans and 11-arylbenzo[b]naphtho[2,3-d]thiophenes. , 1999, Journal of medicinal chemistry.
[24] J. Fleckner,et al. Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar. , 2003, Journal of medicinal chemistry.
[25] T. Saruta,et al. Combination therapy with PPARγ and PPARα agonists increases glucose-stimulated insulin secretion in db/dbmice , 2003 .
[26] Studies on non-thiazolidinedione antidiabetic agents. 3. Preparation and biological activity of the metabolites of TAK-559. , 2004, Chemical & pharmaceutical bulletin.
[27] Takashi Kobayashi,et al. 新規な1,4-ジヒドロピリジン系Ca拮抗薬CS-905の研究(第1報)液体クロマトグラフ(HPLC)法による分配係数(logP)の測定 , 1995 .